We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

DNA2.0 Expands European Presence by Opening UK Office

Read time: Less than a minute

DNA2.0 has announced the expansion of the company’s European operations with the creation of the United Kingdom-based DNA2.0 Ltd.

Michael Dyson, PhD, has been appointed as Managing Director of European Operations and will lead the new venture in the UK as well as DNA2.0’s established office in Basel, Switzerland.

“The opening of our UK headquarters represents a major step in our global growth,” said Jeremy Minshull, President of DNA2.0. “Even in a time of economic uncertainty, the market for gene synthesis and its many applications continues to grow rapidly in Europe. We are confident that European customers will continue to seek out our world-class customer support, fast and reliable turnaround time and the certainty that their intellectual property is completely protected.”

The Company says that, while many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company’s facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0’s two European locations ensure that European customers receive the same PhD-level service and support as their US counterparts.

“The demand in the European marketplace for high quality synthetic genes, delivered quickly and with confidence, is tremendous,” said Dr. Dyson. “We look forward to serving our European customers even more effectively through this new base of operations.”